Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorthe SIREN Study Group and the Crick COVID Immunity Pipeline Consortium
dc.contributor.authorAtti, Ana
dc.contributor.authorInsalata, Ferdinando
dc.contributor.authorCarr, Edward J
dc.contributor.authorOtter, Ashley D
dc.contributor.authorCastillo-Olivares, Javier
dc.contributor.authorWu, Mary
dc.contributor.authorHarvey, Ruth
dc.contributor.authorHowell, Michael
dc.contributor.authorChan, Andrew
dc.contributor.authorLyall, Jonathan
dc.contributor.authorTemperton, Nigel
dc.contributor.authorCantoni, Diego
dc.contributor.authorda Costa, Kelly
dc.contributor.authorNadesalingam, Angalee
dc.contributor.authorTaylor-Kerr, Andrew
dc.contributor.authorHettiarachchi, Nipunadi
dc.contributor.authorTranquillini, Caio
dc.contributor.authorHewson, Jacqueline
dc.contributor.authorCole, Michelle J
dc.contributor.authorFoulkes, Sarah
dc.contributor.authorMunro, Katie
dc.contributor.authorMonk, Edward J M
dc.contributor.authorMilligan, Iain D
dc.contributor.authorLinley, Ezra
dc.contributor.authorChand, Meera A
dc.contributor.authorBrown, Colin S
dc.contributor.authorIslam, Jasmin
dc.contributor.authorSemper, Amanda
dc.contributor.authorCharlett, Andre
dc.contributor.authorHeeney, Jonathan L
dc.contributor.authorBeale, Rupert
dc.contributor.authorZambon, Maria
dc.contributor.authorHopkins, Susan
dc.contributor.authorBrooks, Tim
dc.contributor.authorHall, Victoria
dc.date.accessioned2022-10-18T10:30:02Z
dc.date.available2022-10-18T10:30:02Z
dc.date.issued2022-11-01
dc.identifier281508647
dc.identifier1150db55-8f45-45a4-ad3c-ffb2f9955136
dc.identifier85138830002
dc.identifier.citationthe SIREN Study Group and the Crick COVID Immunity Pipeline Consortium , Atti , A , Insalata , F , Carr , E J , Otter , A D , Castillo-Olivares , J , Wu , M , Harvey , R , Howell , M , Chan , A , Lyall , J , Temperton , N , Cantoni , D , da Costa , K , Nadesalingam , A , Taylor-Kerr , A , Hettiarachchi , N , Tranquillini , C , Hewson , J , Cole , M J , Foulkes , S , Munro , K , Monk , E J M , Milligan , I D , Linley , E , Chand , M A , Brown , C S , Islam , J , Semper , A , Charlett , A , Heeney , J L , Beale , R , Zambon , M , Hopkins , S , Brooks , T & Hall , V 2022 , ' Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination : a nested case-control within the SIREN study ' , Journal of Infection , vol. 85 , no. 5 , pp. 545-556 . https://doi.org/10.1016/j.jinf.2022.09.004en
dc.identifier.issn0163-4453
dc.identifier.otherPubMedCentral: PMC9458758
dc.identifier.urihttps://hdl.handle.net/10023/26212
dc.descriptionFunding: This study was supported by the U.K. Health Security Agency, the U.K. Department of Health and Social Care (with contributions from the governments in Northern Ireland, Wales, and Scotland), the National Institute for Health Research, and grant from the UK Medical Research Council (grant number MR/W02067X/1). This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (CC2087, CC1283), the UK Medical Research Council (CC2087, CC1283), and the Wellcome Trust (CC2087, CC1283).en
dc.description.abstractObjectives To investigate serological differences between SARS-CoV-2 reinfection cases and contemporary controls, to identify antibody correlates of protection against reinfection. Methods We performed a case-control study, comparing reinfection cases with singly infected individuals pre-vaccination, matched by gender, age, region and timing of first infection. Serum samples were tested for anti-SARS-CoV-2 spike (anti-S), anti-SARS-CoV-2 nucleocapsid (anti-N), live virus microneutralisation (LV-N) and pseudovirus microneutralisation (PV-N). Results were analysed using fixed effect linear regression and fitted into conditional logistic regression models. Results We identified 23 cases and 92 controls. First infections occurred before November 2020; reinfections occurred before February 2021, pre-vaccination. Anti-S levels, LV-N and PV-N titres were significantly lower among cases; no difference was found for anti-N levels. Increasing anti-S levels were associated with reduced risk of reinfection (OR 0·63, CI 0·47-0·85), but no association for anti-N levels (OR 0·88, CI 0·73-1·05). Titres >40 were correlated with protection against reinfection for LV-N Wuhan (OR 0·02, CI 0·001–0·31) and LV-N Alpha (OR 0·07, CI 0·009–0·62). For PV-N, titres >100 were associated with protection against Wuhan (OR 0·14, CI 0·03–0·64) and Alpha (0·06, CI 0·008–0·40). Conclusions Before vaccination, protection against SARS-CoV-2 reinfection was directly correlated with anti-S levels, PV-N and LV-N titres, but not with anti-N levels. Detectable LV-N titres were sufficient for protection, whilst PV-N titres >100 were required for a protective effect. Trial registration number ISRCTN11041050
dc.format.extent12
dc.format.extent3762473
dc.language.isoeng
dc.relation.ispartofJournal of Infectionen
dc.subjectSARS-CoV-2en
dc.subjectNeutralising antibodiesen
dc.subjectSARS-CoV-2 serologyen
dc.subjectReinfectionen
dc.subjectImmunityen
dc.subjectQR180 Immunologyen
dc.subject3rd-DASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectMCCen
dc.subject.lccQR180en
dc.titleAntibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination : a nested case-control within the SIREN studyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doi10.1016/j.jinf.2022.09.004
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record